CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells

摘要

Hepatocellular carcinoma (HCC) is one of the most common tumor types, and is the third leading cause of cancer mortalities worldwide. A large number of patients with HCC are diagnosed at a late stage when the curative treatment of surgical resection and liver transplantation are no longer applicable. Sorafenib has been proved to improve overall survival in advanced HCC; however, drug resistance is common. The present study reported that the CSN5 is correlated with sorafenib resistance of the HCC cell line HepG2/S. Following silencing of CSN5, resistance to sorafenib was reversed, and multi-drug-resistance proteins, including as adenosine triphosphate binding cassette (ABC) B1, ABCC2 and ABCG2 as well as CDK6, cyclin D1 and B-cell lymphoma 2 were downregulated. In addition, it was demonstrated that the integrin beta-1, transforming growth factor-beta 1 and nuclear factor-kappa B pathways were modified by CSN5.